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Highlights: 1 
 MRD positivity in ALL is a major risk factor for relapse and poor outcomes 2 
 We evaluated the impact of MRD levels before alloHSCT on outcomes of Ph+ 3 
ALL 4 
 Patients with measurable levels of MRD have a higher risk of relapse  5 
 Achieving a MRD negativity should be a prerequisite for successful alloHSCT 6 
Abstract 7 
Background. Allogeneic stem cell transplantation (alloHSCT) in first complete remission 8 
(CR1) remains the consolidation therapy of choice in Philadelphia positive acute 9 
lymphoblastic leukemia (Ph+ ALL).  The prognostic value of measurable levels of minimal 10 
residual disease (MRD) at time of conditioning is a matter of debate.  11 
Methods. We analyzed the predictive relevance of MRD levels before transplant on the 12 
clinical outcome of Ph+ALL patients treated with chemotherapy and imatinib in 2 13 
consecutive prospective clinical trials. MRD evaluation before transplant was available for 65 14 
of the 73 patients who underwent an alloHSCT in CR1.  15 
Results. A complete or major molecular response at time of conditioning was achieved in 24 16 
patients (37%) while 41 (63%) remained carriers of any other positive MRD level in the bone 17 
marrow. The MRD negativity at time of conditioning was associated with a significant 18 
benefit in terms of risk of relapse at 5 years with a relapse incidence of 8% compared to 39% 19 
of patients with MRD positivity (p=0.007). However, thanks to the post-transplant use of 20 
tyrosine kinase inhibitors (TKIs), the disease free survival probability was 58% vs 41% 21 
(p=0.17) and the overall survival was 58% vs 49% (p=0.55) in MRD negative compared to 22 
MRD positive patients, respectively. The cumulative incidence of non relapse mortality was 23 
similar in the 2 groups.  24 
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Conclusions. Achieving a complete molecular remission before transplant reduces the risk of 1 
leukemia relapse even though TKIs may still rescue some patients relapsing after transplant. 2 
 3 
Keywords: Acute Lymphoblastic Leukemia 4 
Allogeneic transplantation 5 
Minimal Residual Disease (MRD) 6 
 7 
Introduction 8 
In the pre-tyrosine kinase inhibitors (TKIs) era, Philadelphia chromosome positive 9 
(Ph+) acute lymphoblastic leukemia (ALL) marked the most unfavorable subgroup of adult 10 
ALL and the overall survival observed in unselected series of patients was less than 20%, 11 
even when allogeneic hematopoietic stem cell transplantation (alloHSCT) was offered 
1,2
. 12 
The incorporation of TKIs, most commonly imatinib, into the standard ALL chemotherapy 13 
has substantially improved the outcomes mainly as a consequence of an improved rate of 14 
complete responses 
3-6
, a longer duration of remission 
3,5,7,8
 and an increased proportion of 15 
patients to whom an alloHSCT transplantation could be offered in first complete remission 16 
(CR1) 
3,4,9
. To date alloHSCT remains the only treatment for which a definitive curative 17 
potential has been demonstrated in Ph+ ALL, even though promising durable remission have 18 
been demonstrated also for some patients treated with TKI based treatments 
7,10,11
. The 19 
outcome of alloHSCT is largely dependent on the non-relapse mortality (NRM) and post-20 
transplant relapse. While some improvement in reduction of NRM has been achieved, relapse 21 
remains a major cause of treatment failure 
6
. In childhood and adult ALL patients, recent 22 
studies have provided reasonable support to suggest an inferior outcome of patients 23 
undergoing alloHSCT with measurable level of MRD at time of conditioning 
12-14
. Since in 24 
Ph+ ALL a deeper molecular response is potentially achievable with innovative targeted 25 
therapies, such as second and third-generation TKIs or immunotherapy 
9-11,15-18
, an accurate 26 
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evaluation of MRD values before alloHSCT is mandatory and should guide the clinical 1 
decision making process. Therefore, we analyzed the prognostic value of the MRD level at 2 
time of conditioning before alloHSCT in patients enrolled into 2 consecutive prospective 3 
clinical trials conducted within the Northern Italy Leukemia Group (NILG).  4 
  5 
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Patients and methods 1 
Patients, Diagnoses, and Minimal Residual Disease evaluations 2 
One hundred and six consecutive Ph+ ALL adult patients (≥ 18 years), treated front-3 
line with chemotherapy and imatinib (target dose 800-600 mg daily) were analysed. Detailed 4 
treatment descriptions of the 2 trials were reported previously 
5,19
 and according to the study 5 
design all patients in first complete remission (CR1) were eligible to perform an alloHSCT 6 
provided that a HLA identical related or unrelated donor could be identified. Individual levels 7 
of MRD were determined in the bone marrow and peripheral blood by quantitative 8 
polymerase chain reaction (RQ-PCR) according to validated methods 
20-22
. Briefly, BCR-9 
ABL level was expressed as ratio between BCR-ABL copy number and ABL copy number, 10 
both calculated on a plasmid dilution standard curve (Normalized Copy Number). Sensitivity 11 
and Quantitative Range (QR) of RQ-PCR method were defined according to European 12 
guidelines 
20,22
. Sensitivity was 10 copies in all the experiments and  QR varied from 100 and 13 
10 copies. MRD level was expressed as logarithmic reduction of BCR-ABL level detected at 14 
fixed time point respect to diagnosis and was obtained by dividing BCR-ABL level at the 15 
selected time point by BCR-ABL level at diagnosis 
21
. Complete molecular response was 16 
defined as undetectable disease and major molecular response was defined as > 4 log MRD 17 
reduction in bone marrow derived mononuclear cells. The post-transplant treatment with 18 
TKIs and/or donor lymphocyte infusions (DLI) was left free to each individual physician 19 
discretion.  20 
The studies were approved by the institutional review board of all participating 21 
institutions, conducted in accordance with the declaration of Helsinki and registered with the 22 
National Clinical Trial Identifier numbers NCT00358072 (trial 09/00) and NCT00358072 23 
(trial 10/07).  24 
 25 
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Study endpoints and statistical methods 1 
MRD evaluation was performed in all patients before alloHSCT. Patients who 2 
achieved a complete or major molecular response at time of conditioning were defined as 3 
MRD negative (MRD-), while patients carriers of any other positive MRD level in the bone 4 
marrow derived mononuclear cells were defined as MRD positive (MRD+). The endpoints of 5 
the study were defined according to the Statistical Guidelines for EBMT 
23
. The overall 6 
survival (OS) was defined as the probability of survival irrespective of disease state at any 7 
point in time from transplantation. Patients living at their last follow-up were censored. 8 
Disease free survival (DFS) was measured from the time of alloHSCT until relapse or death. 9 
The cumulative incidence of relapse (RI) was calculated as the time from transplantation to 10 
the first evidence of recurrence or progression of disease, with death with no prior relapse or 11 
progression as competing risk. Similarly, the non-relapse mortality (NRM) was defined as the 12 
probability of dying without a previous occurrence of relapse or progression, considering 13 
relapse or progression as competing risk. Relapse was defined by recurrence of more than 5% 14 
of lymphoblasts in peripheral blood or in the bone marrow and/or by the presence of 15 
extramedullary disease.  16 
Baseline continuous characteristics were presented as median with range, and were 17 
compared among the two MRD groups using T-test or Mann- Whitney as appropriate. 18 
Categorical variables were reported with absolute and percentage frequencies and compared 19 
with Chi-squared test or Fisher’s exact test. OS and DFS were estimated by the Kaplan-Meier 20 
method and any differences in MRD groups were evaluated with log-rank test. Competitive 21 
risk approach was applied to estimate cumulative incidence of both relapse and non-relapse 22 
mortality; Gray’s test was used to compare the study groups. To evaluate transplant effect on 23 
OS, a Cox proportional hazard model with time dependent variable has been estimate on 24 
patients in CR1. 25 
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All reported P values are two-sided and statistical significance was set a P value less than 1 
0.05. All analyses were performed with the use of R software, version 3.1.2 2 
Results 3 
Among 106 adult patients (median age 44.1, range 18.5-66.1) with newly diagnosed 4 
Ph+ ALL enrolled into 2 consecutive clinical trials, 100 patients (94%) achieved CR after 5 
induction, and 73 of these patients underwent an alloHSCT in CR1. In the remaining 27 6 
patients, the reasons for not undergoing alloHSCT were: absence of donor (n=8), early death 7 
(n=4), poor performance status (n=1), early relapse (n=12), patient refusal (n=1) and 8 
unknown (n=1).  Among these 73 patients, the MRD status measured at time of conditioning 9 
was available for 65 patients (89%) who are the subject of this report (Figure 1). The overall 10 
survival of patients who received or not an alloHSCT in first remission is shown in Figure 2. 11 
However, to overcome the bias of time to transplant, the therapeutic efficacy of transplant 12 
was tested by a Cox proportional hazard model with transplant as a time-dependent variable. 13 
When considering the 100 patients in CR1, the alloHSCT does not reduce significantly the 14 
risk of death (Hazard Ratio=0.68 [95%CI: 0.39-1.20], P=0.1840).  15 
Twenty-four patients (37%) were in complete or major molecular response 16 
(undetectable disease or > 4 log MRD reduction) at time of conditioning (MRD- group), 17 
while 41 (63%) remained carriers of any positive MRD level in the bone marrow (MRD+ 18 
group) ranging from 1.3x10
-4 
to 2x10
-1. Patients’ characteristics were similar between MRD+ 19 
and MRD- groups, except for a higher hemoglobin levels and a predominance of male gender 20 
in MRD- group (Table 1). Thirty-one patients received alloHSCT from a sibling and 34 from 21 
unrelated donor. The conditioning regimen to transplant was myeloablative in 83% and 22 
reduced intensity in 17% of patients. The stem cell source was the bone marrow in 18.5%, the 23 
peripheral blood in 78.5% and cord blood in the remaining 3% of patients.  24 
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For the patient cohort analyzed for MRD before transplant (n=65), the 5 years OS was 52% 1 
(95% CI: 41% - 66%). The MRD negativity at time of conditioning was associated with a 2 
significant benefit in terms of risk of hematologic relapse at 5 years with a CIR of 8% (95% 3 
CI: 2% - 33%) compared to 39% (95% CI: 26% - 58%) of patients with MRD positivity 4 
(p=0.007) (Figure 3A). Nonetheless, the  DFS and the OS probability at 5 years were not 5 
significantly different in MRD- compared to MRD+ patients (58% [95% CI: 42% - 82%]  vs 6 
41% [95% CI: 29% - 60%], p=0.17 and 58% [95% CI: 42% - 82%] vs 49% [95% CI: 36% - 7 
67%], p=0.55, respectively) (Figure3B and 3C), probably as the consequence of an effective 8 
post-transplant treatment with TKIs and/or DLI. Patients who received TKIs after transplant 9 
were almost invariably MRD positive and about half of them converted to a stable MRD 10 
negative condition. Patients, who did not achieve a molecular remission, invariably suffered a 11 
subsequent clinical relapse. Among the 33 patients receiving TKIs post-transplant, imatinib 12 
was the more frequently used:  imatinb (n=22), dasatinib (n=8), imatinib followed by 13 
dasatinib (n=2) and dasatinib followed by ponatinib (n=1). Not surprisingly, the need of post-14 
transplant treatment with TKIs and/or DLI was significantly higher among MRD+ group 15 
compared with MRD- group (61% vs 33% p=0.034) (Figure 4).  The cumulative incidence of 16 
non relapse mortality at 5 years was similar in MRD- compared to that of MRD+ group (33% 17 
[95% CI; 19% - 60%]  vs 20% [95% CI: 10% - 37%], p=0.22). Different levels of MRD 18 
positivity before transplant (≤ 10-4 level, >10-4 to < 10-3, and ≥10-3) did not translate into a 19 
significantly different clinical outcome.   20 
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Discussion 1 
To our knowledge, this is one of the largest prospective analysis evaluating the long 2 
term impact of pre-transplant MRD level on the clinical outcome of Ph+ ALL patients 3 
undergoing alloHSCT. Our results confirm previous reports indicating that the addition of 4 
imatinib improved the CR rate (94%) and the proportion of adult patients with Ph+ ALL to 5 
whom an alloHSCT could be offered 
4,6,8,9
. The very long-term follow-up of this analysis 6 
indicates that survival can be achieved close to 50% for patients with Ph+ ALL after 7 
alloHSCT, a significant improvement compared to the pre-imatinib era 
1-3
. Our study 8 
confirms that alloHSCT can be offered to a significant proportion of Ph+ALL patients and 9 
remains the most active post-remissional treatment of choice. The main finding of our study 10 
is that patients undergoing alloHSCT with measurable levels of MRD have a significant 11 
higher risk of relapse after transplant. In agreement with our results, very recently the Japan 12 
Society for Hematopoietic Cell Transplantation found in a retrospective analysis of data from  13 
432 adult Ph+ ALL patients that the incidence of relapse in MRD negative patients at 14 
transplant was significantly lower compared to patients transplanted in MRD positivity (19% 15 
vs 29%, respectively) 
24
. Accordingly, any effort should be done to achieve a deep molecular 16 
response before the beginning of the conditioning regimen. Although in our study the 17 
significant reduction of relapse did not translate into a clear benefit in terms of  DFS and OS, 18 
this result is due  to the remarkable NRM observed in patients undergoing transplantation 19 
being MRD negative and to the effective response frequently obtained with the  post-20 
transplant use of TKIs with or without DLI.  In keeping with this interpretation, treatments 21 
after transplant with TKIs and/or DLI were significantly more used among MRD+ group 22 
compared with MRD- group. Moreover, patients who received a TKI based treatment had the 23 
chance to convert to a stable MRD negative condition in half the cases, suggesting that TKIs 24 
treatment, given as salvage option after transplantation, may be an effective rescue for a 25 
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remarkable proportion of patients. It is worth noting that previous experiences that explored 1 
the use of prophylactic imatinib and nilotinib maintenance after transplantation 
25,26
 showed a 2 
high efficacy of treatment in preventing relapse, but this was hampered by a high rate of early 3 
discontinuation due to poor tolerability 
25,26
. Unfortunately, our database did not contain 4 
specific data about the characteristics and the complications of post-HSCT treatments (i.e. 5 
DLI cell doses, cumulative incidence of chronic GvHD, TKIs related complications) nor 6 
information about the presence of specific ABL mutations such as the T315I. Therefore, a 7 
formal evaluation of their impact in terms of comorbidity, quality of life and treatment 8 
response is limited. Treatment with TKIs after alloHSCT can be difficult to tolerate and may 9 
be followed by a high rate of early discontinuation. Therefore, a careful risk assessment of 10 
each patient with Ph+ ALL, may lead to timely initiation of an effective treatment with TKIs 11 
and to avoid it, if not strictly necessary. In this context, the information of this study is 12 
potentially very useful and suggests to limit TKIs prophylactic use to patients at high risk of 13 
relapse, such as MRD positive patients before transplant and to apply a MRD-driven strategy 14 
in MRD negative patients. Our results suggest that a deep molecular response before 15 
transplant predict a better outcome, but in agreement with the EBMT results 
6
, we have no 16 
evidence that increasing levels of MRD positivity are associated with different risk of relapse, 17 
even though a larger group of patients is requested to validate this result. 
 
18 
The concept that alloHSCT remains the standard of care for any patient suitable for 19 
the procedure and with an available donor has been recently underlined by the French clinical 20 
trial recently published by Chalandon et al 
9
. However, patients achieving an early molecular 21 
CR through the combination of specific targeted therapies plus chemotherapy may identify 22 
patients who may be possibly cured without alloHSCT. In this regard, a recent study showed 23 
that a negative MRD status after three months and beyond of a TKIs based chemotherapy 24 
program was associated with a low risk of relapse and an OS above 60% at 3–5 years in 25 
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patients excluded from HSCT as first-line therapy 
7
. Moreover, a more recent phase 2 trial, 1 
that examined the combination of chemotherapy with ponatinib, showed that long-term DFS 2 
was not affected by alloHSCT in patients achieving MRD negative status 
11
. These interesting 3 
results confirm the importance of achieving a complete molecular remission, even suggesting 4 
that the paradigm of myeloablative alloHSCT, as indispensable post-remission therapy in 5 
adult Ph+ ALL, may be subject to revision. Moreover, these latter results 
11
 strongly 6 
emphasized the absolute need to reduce the early and late NRM to an acceptable level and 7 
this may lead to dispute the need of a myeloablative conditioning (MAC) regimen in most of 8 
these patients. In this respect, Buchanova et al. recently showed that reduced intensity 9 
conditioning (RIC) alloHSCT may represent a viable alternative to MAC alloHSCT for 10 
patients with Ph+ ALL that have achieved a MRD negative status, mainly for older patients, 11 
who were at a greater risk of NRM 
27
. In our study, only 14 patients received a bone marrow 12 
(n=12 ) or a cord blood (n= 2) graft, while a non myeloablative conditioning regimen was 13 
given only to 11 patients. These small numbers prevent drawing any meaningful 14 
interpretation from our results. Yet, further studies specifically designed to test prospectively 15 
whether or not different stem cell source or conditioning regimens at lower intensity may 16 
prove equally effective and safe for patients achieving a negative MRD status need to be 17 
developed.  18 
In conclusion, our results reinforce evidence that patients undergoing alloHSCT with 19 
measurable level of MRD clearly show an inferior outcome after transplant in terms of 20 
relapse incidence and this information is certainly useful for an effective HSCT planning. 21 
Indeed, an effort to achieve a convincing molecular CR should be pursued and considered an 22 
essential prerequisite for successful alloHSCT along with the reduction of the NRM. In this 23 
respect, the future challenge will be to achieve a deep molecular response thanks to an 24 
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appropriate combination of the available therapies, with third generation TKIs with or 1 
without new antibody or cellular therapies 
28-30
.  2 
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Figure Legends 12 
Figure 1. Study flow 13 
Figure 2. Overall survival according to alloHSCT in first remission  14 
Figure 3 A-B-C. Cumulative incidence of hematologic relapse, DFS and OS by MRD group 15 
Figure 4. Number of post-transplant treatments by MRD group  16 
 17 
Table 1. Patients’ characteristics according to MRD group 18 
Characteristics All patients 
(N=65) 
MRD negative (N=24) MRD positive (N=41) P 
Age years , median (range) 43.2 (18.5-62.4) 45 (21.4-58.2) 42.7 (18.5-62.4) 0.8340 
 
Male sex (%) 31 (47.7) 16 (66.7) 15 (36.6) 0.0191 
 
WBC, X 10
9
/L, median 
(range) 
15 (0.9-680) 27.7 (0.9-350) 12 (1.1-680) 0.1238 
 
Hemoglobin, g/dL, median 
(range) 
9.6 (3.7-16.5) 11.4 (5.4-14.6) 9 (3.7-16.5) 0.0191 
 
Platelets, X 10
9
/L, median 
(range) 
37 (3-336) 41 (4-336) 34 (3-325) 0.4374 
 
LDH, U/L median (range) 795 (65-8104) 1231 (353-8104) 715 (65-6194) 0.1147 
 
Conditioning regimen (%) 
Reduced intensity  
Myeloablative 
 
11 (16.9) 
54 (83.1) 
 
4 (16.7) 
20 (83.3) 
 
7 (17.1) 
34 (82.9) 
 
1.00 
Donor type (%) 
Sibling 
Unrelated 
 
31 (47.7) 
34 (52.3) 
 
13 (54.2) 
11 (45.8) 
 
18 (43.9) 
23 (56.1) 
 
0.4240 
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Graft type (%) 
Bone marrow 
Peripheral blood 
Cord blood 
 
12 (18.5) 
51 (78.5) 
2 (3.1) 
 
 
3 (12.5) 
20 (83.3) 
1 (4.2) 
 
 
9 (22) 
31 (75.6) 
1 (2.4) 
 
0.5749 
§ MRD negative vs MRD positive 1 
WBC: white blood cells; LDH: lactate dehydrogenase 2 
 3 
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